Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
Key claim: A multi-disciplinary exercise-plus-nutrition intervention is being tested against standard advice to slow declines in muscle mass, strength, and physical function in adults 65+ with type 2 diabetes and obesity on weekly semaglutide.
Abstract
This study aims to test whether a multi-disciplinary intervention involving exercise and nutrition can slow down the decline in physical function, muscle strength and mass in older adults (aged 65 and above) with Type 2 diabetes (T2D) and obesity treated with Semaglutide.
The main questions it aims to answer are:
In older people with T2D and obesity, treated with Semaglutide, does a multi-disciplinary intervention of exercise and nutrition compared to standard health recommendations:
- Reduce the rate of decline in muscle mass?
- Reduce the rate of decline in muscle strength?
- Reduce the rate of decline in physical function?
Participants will:
Administer Semaglutide once weekly for 6 months. Visit the clinic once every 8 weeks for checkups and tests. Keep a diary of their food consumption. Participants in the intervention group will participate in an online exercise program and will receive personal nutritional counseling.
Why this matters
As GLP-1 prescribing expands into older adults, sarcopenia risk from rapid weight loss has become the dominant safety concern shadowing the AOM-as-geroprotector narrative. This trial joins a small but growing set of registered adjunct protocols (protein/HMB, resistance training, structured nutrition) attempting to convert that concern into a testable mitigation strategy — but as of now it is a design, not a result, and the muscle-preservation claims circulating in trend media still outrun the evidence base.